YOLFTbeta
30

Anhui Wanbang Pharmaceutical Technology Co.,Ltd.

301520 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

58.05CNY-7.47 (-11.40%)

Price History

Full chart

Market Stats

Previous Close65.52
Open58.21
Day Range58.00 – 63.50
52-Week Range23.18 – 88.88
Volume11.25M
Market Cap5.39B
P/E (TTM)1445.00
Forward P/E0.00
EPS0.04
Dividend Yield0.52%
Beta0.23
50-Day Avg64.22
200-Day Avg44.47

About

Anhui Wanbang Pharmaceutical Technology Co.,Ltd. provides pharmaceutical research and clinical research services in China. The company offers service platform for pharmaceutical research, raw materials, clinical research, medical device services, biological sample analysis, SMO service, and statistical analysis. It also provides precision nutrition cooperation and ecosystem platform; and drug platform. The company was incorporated in 2006 and is based in Hefei, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMs. Chunlei Tao
  • Employees370
  • HeadquartersNo. 299, Huolongdi Road, Hefei, China, 230031, China
  • Websitehttps://www.ahwbyy.cn

Leadership

  • Ms. Chunlei TaoGM & Chairman of the Board · b. 1971
  • Ms. Yan ZhouDeputy General Manager · b. 1986
  • Mr. Yang XuDeputy General Manager · b. 1984

Financials

Income Statement

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Total Revenue260.78M341.81M379.09M274.18M
Growth (%)-+31.07%+10.91%-27.67%
Cost of Revenue129.39M174.53M229.05M203.17M
Gross Profit131.39M167.27M150.04M71.01M
Gross Margin50.38%48.94%39.58%25.90%
Operating Expense27.06M54.99M88.53M55.28M
Operating Income104.32M112.28M61.51M15.73M
Operating Margin40.00%32.85%16.22%5.74%
EBITDA116.64M129.34M104.62M52.88M
EBITDA Margin44.73%37.84%27.60%19.29%
Net Income98.73M108.09M85.53M36.43M
Net Income Margin37.86%31.62%22.56%13.29%
R&D15.97M34.52M60.68M32.93M
R&D as % of Total Revenue6.12%10.10%16.01%12.01%
Interest Expense7.74K115.7900
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%

Balance Sheet

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Total Assets404.60M1.54B1.60B1.60B
Total Liabilities72.98M80.58M90.44M87.13M
Total Equity331.62M1.46B1.51B1.52B
Cash186.15M253.50M179.29M150.30M

Cash Flow

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow72.32M71.92M46.84M-7.92M
Capital Expenditure50.70M85.97M41.82M19.22M
Free Cash Flow21.63M-14.05M5.02M-27.14M
Dividends Paid--31.14M23.21M
FCF to OCF29.90%-19.53%10.71%342.59%
Dividend Paid to FCF--620.58%-85.50%

Earnings

Report DateSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
EPS Estimate-------------
EPS Actual0.250.330.320.270.240.080.130.160.070.04-0.000.000.00
Surprise-------------
Timing-------------

Key Statistics & Ratios

Market Cap5.39B
Enterprise Value4.45B
Trailing P/E1445.00
Forward P/E0.00
Price / Sales21.63
Price / Book3.60
EPS0.04
Book Value16.11
Revenue (TTM)248.98M
Gross Profit (TTM)53.98M
EBITDA672.52K
Profit Margin1.57%
Operating Margin6.12%
Return on Equity0.48%
Return on Assets-0.59%
Shares Outstanding93.17M
Shares Float32.78M
Beta0.23
Dividend Yield0.52%
Dividend Rate0.30
Payout Ratio7.14%